Actively Recruiting
Intravenous Tenecteplase Treatment Before Transfer for Thrombectomy in Acute Basilar Artery Stroke Occurring 4.5 to 24 Hours After Symptoms
Led by Xuanwu Hospital, Beijing · Updated on 2026-03-19
316
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of intravenous tenecteplase given before transferring patients with acute ischemic stroke caused by basilar artery occlusion BAO to a specialized center for thrombectomy. This trial focuses on patients who have had stroke symptoms for 4.5 to 24 hours and aims to improve treatment outcomes during the transfer process. The study is a multicenter, randomized controlled trial with an open-label design and blinded outcome assessments. Participants will be randomly assigned to receive either a single intravenous bolus of tenecteplase at 0.25 mgkg up to 25 mg before transfer or standard treatment without tenecteplase. The drug is administered over 5 to 10 seconds, and transfer to an endovascular capable center ECC for thrombectomy starts immediately afterward. The control group will receive standard care and be transferred directly for thrombectomy following current guidelines. Throughout the study, participants will be monitored for functional recovery at 90 days using the modified Rankin Scale mRS and other clinical outcomes such as early neurological improvement, arterial recanalization, and reperfusion success. Assessments will include imaging, clinical evaluations, and quality of life measures. The study will also track safety and adverse events during and after treatment, with follow-up lasting up to 90 days after enrollment.
CONDITIONS
Brief Title
Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours
Research Team
J
Junwei Hao, MD
G
Gaoting Ma, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here